Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJW72O)

Drug Name

SB-416 Drug Info

Synonyms

UNII-344PKU9JSY; 344PKU9JSY; 63589-10-6; SB-416; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-4-[(4-methoxyphenyl)amino]-9,10-dioxo-, monosodium salt; CHEMBL401735; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-4-[(4-methoxyphenyl)amino]-9,10-dioxo-, sodium salt (1:1); 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-4-((4-methoxyphenyl)amino)-9,10-dioxo-, monosodium salt; 2-Anthracenesulfonic acid, 1-amino-9,10-dihydro-4-((4-methoxyphenyl)amino)-9,10-dioxo-, sodium salt (1:1); EINECS 264-344-5; AC1Q1VH1

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 23680506
CAS Number: CAS 63589-10-6
TTD Drug ID: DMJW72O

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting P2Y purinoceptor 2 (P2RY2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Diquafosol	DM64QG9	Dry eye disease	9E1Z	Phase 3	[2]
INS-37217	DMF93RQ	Cystic fibrosis	CA25	Phase 2	[2]
INS 316	DMTHMEI	Lung cancer	2C25.0	Discontinued in Phase 3	[3]
PSB-0963	DMBDVJ1	Discovery agent	N.A.	Investigative	[4]
RB 2	DMCEFUW	Discovery agent	N.A.	Investigative	[1]
UTPgammaS	DMKLB4O	Discovery agent	N.A.	Investigative	[5]
Acid blue 25	DMCU6XV	Discovery agent	N.A.	Investigative	[4]
5BrUTP	DMEVRH4	Discovery agent	N.A.	Investigative	[5]
2-thioUTP	DMJZ5V0	Discovery agent	N.A.	Investigative	[6]
MDT-006	DMSF4UI	Constipation	DD91.1	Investigative	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
P2Y purinoceptor 2 (P2RY2)	TTOZHQC	P2RY2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Combinatorial synthesis of anilinoanthraquinone derivatives and evaluation as non-nucleotide-derived P2Y2 receptor antagonists. Bioorg Med Chem Lett. 2008 Jan 1;18(1):223-7.
2	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
3	Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol. 2001 Aug;32(2):122-8.
4	Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
5	Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol. 1995 Sep;116(1):1619-27.
6	Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.
7	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 324).